Stay updated with breaking news from Multiple Secondary Endpoints. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus
Biopharma stock Insmed (Nasdaq: INSM) doubles on Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial Table: IMU-838 Shows Acceleration of Time to Clinical Improvement High-risk patients and patients aged over 65 years experienced a more substantial treatment benefit from IMU-838 than in the general patient population: - The 75% probability [5] to reach clinical improvement (based on investigator assessment) was accelerated by 3.8 days in IMU-838 treated high-risk patients [6], as compared to placebo (FAS). - The 75% probability [5] to reach clinica...